Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

61.36
-1.9900-3.14%
Post-market: 61.360.00000.00%16:20 EST
Volume:920.14K
Turnover:56.59M
Market Cap:2.32B
PE:-11.31
High:63.07
Open:62.80
Low:60.46
Close:63.35
52wk High:99.50
52wk Low:30.82
Shares:37.75M
Float Shares:32.58M
Volume Ratio:0.42
T/O Rate:2.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4247
EPS(LYR):-3.9613
ROE:-34.78%
ROA:-22.61%
PB:4.04
PE(LYR):-15.49

Loading ...

Disc Medicine (IRON) Receives a Buy from LifeSci Capital

TIPRANKS
·
Yesterday

Disc Medicine CFO Jean M. Franchi Disposes of Common Shares

Reuters
·
Feb 20

Chief Commercial Officer Pamela Stephenson Reports Disposal of Disc Medicine Inc. i Common Shares

Reuters
·
Feb 18

Disc Medicine CEO John D. Quisel Reports Sale of Common Shares

Reuters
·
Feb 18

Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says

MT Newswires Live
·
Feb 18

Wedbush Adjusts Price Target on Disc Medicine to $88 From $110, Maintains Outperform Rating

MT Newswires Live
·
Feb 17

Disc Medicine Inc. i details bitopertin regulatory update and clinical trial progress

Reuters
·
Feb 17

Disc Medicine Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Feb 17

Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod

Reuters
·
Feb 17

Disc Medicine price target lowered to $75 from $120 at Morgan Stanley

TIPRANKS
·
Feb 17

Disc Medicine Exec Says That IF Late-Stage Trial Succeeds, Co Will Seek Approval Through the Traditional Pathway Rather Than the Accelerated Route – Conf Call

THOMSON REUTERS
·
Feb 17

Disc Medicine Exec Says It Expects Late-Stage Data for Bitopertin in Q4 This Year – Conf Call

THOMSON REUTERS
·
Feb 17

Disc Medicine Exec Says the Policy Debate Over Accelerated Approval Has Stretched Across Multiple Administrations, and Recent Decisions Show Regulators Are Taking an "Increasingly Stringent" View of When Such Approvals Are Appropriate – Conf Call

THOMSON REUTERS
·
Feb 17

Disc Medicine Addresses FDA Rejection of Bitopertin Filing

TIPRANKS
·
Feb 17

Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Feb 17

Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path

TIPRANKS
·
Feb 17

FDA Delays Disc Medicine's Rare Disease Drug

Benzinga_recent_news
·
Feb 17

Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)

TIPRANKS
·
Feb 16

Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval

Dow Jones
·
Feb 14

BUZZ-Disc Medicine dives as FDA declines to approve rare disease drug

Reuters
·
Feb 14